HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

An evaluation of the effects of an angiotensin receptor blocker on health-related quality of life in patients with high-normal blood pressure (prehypertension) in the Trial of Preventing Hypertension (TROPHY).

Abstract
The Trial of Preventing Hypertension (TROPHY) demonstrated the feasibility of possibly reducing the incidence of hypertension with the angiotensin receptor blocker candesartan compared with placebo. The long-term benefits of pharmacologic therapy in high-normal blood pressure, or prehypertension are not known, and the long-term effect on health-related quality of life (HRQL) has not been determined. An analysis of covariance model was used to assess treatment differences from baseline in the HRQL scores using Short Form (SF)-36, and component measures at subsequent visits. Of the 809 randomized patients, 734 had both baseline and > or =1 HRQL follow-up assessment: 95% (379 of 397) of patients receiving candesartan and 91% (355 of 388) of patients receiving placebo. There were no statistically significant between-group differences in least-squares mean physical component survey and mental component survey scores or the individual scales at each scheduled visit relative to baseline values (P >.05). In TROPHY, patients with prehypertension had relatively high baseline HRQL, and HRQL was maintained with the angiotensin receptor blocker candesartan over both the 2-year treatment period and a total 4-year trial period.
AuthorsSetareh A Williams, Eric L Michelson, Valerie A Cain, Min Yang, Shawna D Nesbitt, Brent M Egan, Stevo Julius, TROPHY Study Investigators
JournalJournal of clinical hypertension (Greenwich, Conn.) (J Clin Hypertens (Greenwich)) Vol. 10 Issue 6 Pg. 436-42 (Jun 2008) ISSN: 1524-6175 [Print] United States
PMID18550933 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Angiotensin II Type 1 Receptor Blockers
  • Benzimidazoles
  • Biphenyl Compounds
  • Placebos
  • Tetrazoles
  • candesartan
Topics
  • Adult
  • Aged
  • Angiotensin II Type 1 Receptor Blockers (therapeutic use)
  • Benzimidazoles (therapeutic use)
  • Biphenyl Compounds
  • Double-Blind Method
  • Female
  • Humans
  • Hypertension (epidemiology, prevention & control)
  • Incidence
  • Male
  • Middle Aged
  • Placebos
  • Quality of Life
  • Surveys and Questionnaires
  • Tetrazoles (therapeutic use)
  • Treatment Outcome
  • United States (epidemiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: